New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 3, 2013
10:00 EDTMNK, ASGN, ECL, FOXA, CLDX, ROL, MAN, CTAS, MMLP, RHI, GMT, CQPOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 21st Century Fox (FOXA) initiated with a Buy at Needham... Cheniere Energy Partners (CQP) initiated with an Outperform at RBC Capital... Cintas (CTAS) initiated with an Outperform at RBC Capital... Ecolab (ECL) initiated with an Outperform at RBC Capital... GATX Corp. (GMT) initiated with an Equal Weight at Stephens... Manpower (MAN) initiated with a Sector Perform at RBC Capital... On Assignment (ASGN) initiated with an Outperform at RBC Capital... Robert Half (RHI) initiated with an Outperform at RBC Capital... Rollins (ROL) initiated with a Sector Perform at RBC Capital... Mallinckrodt (MNK) initiated with a Buy at BofA/Merrill... Martin Midstream Partners (MMLP) initiated with a Neutral at BofA/Merrill... Celldex (CLDX) initiated with a Buy at Guggenheim.
News For FOXA;CQP;CTAS;ECL;GMT;MAN;ASGN;RHI;ROL;MNK;MMLP;CLDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 18, 2014
07:22 EDTRHIRobert Half price targert raised to $62 from $55 at Deutsche Bank
Deutsche Bank raised its price target for Robert Half shares to $62 saying it sees another 10%-15% of upside in the coming year. It reiterates a Buy rating on the stock.
November 17, 2014
16:24 EDTCLDXOn The Fly: Closing Wrap
Stocks on Wall Street were quiet and traded in a fairly narrow range for their sixth straight session, despite a "merger Monday" that saw over $100B in deals announced. The Dow and S&P, which began the week near record levels, passed back and forth across the flat line several times during the day, though the Nasdaq weakened early in the session and never really recovered. ECONOMIC EVENTS: In the U.S., industrial production fell 0.1% in October, missing expectations for it to have risen 0.2% from the prior month. October capacity utilization came in at 78.9%, which fell short of the expected 79.3% rate. The Empire State manufacturing index, which reflects manufacturing activity in the New York region, rose 4 points to 10.2 in November, which was generally in-line with the consensus forecast. In Asia, Japan's GDP unexpectedly shrank an annualized 1.6% last quarter, missing projections for a 2.2% gain and sinking its economy into a recession. COMPANY NEWS: Actavis (ACT) gained $4.17, or 1.71%, to $247.94 after confirming that it agreed to acquire Allergan (AGN) for a combination of $129.22 in cash and 0.3683 Actavis shares valued at approximately $66B, or $219 per Allergan share. Valeant Pharmaceuticals (VRX), which had been in a contentious fight to buy Allergan, commented that it "cannot justify to its own shareholders" paying a price of $219 or more per share for the Botox maker, whose stock rose $10.55, or 5.31%, to $209.20... Halliburton (HAL), conversely, fell $5.85, or 10.62%, to $49.23 after it agreed to acquire Baker Hughes (BHI) in a stock and cash transaction valued at $78.62 per Baker Hughes share, representing an enterprise value of $38B. When the deal talks were first reported by The Wall Street Journal last week, antitrust concerns were highlighted by analysts, but Halliburton said it had agreed to divest businesses that generate up to $7.5B in revenues, if required by regulators, and agreed to pay a fee of $3.5B if the transaction terminates due to a failure to obtain required approvals. Baker Hughes rose $5.34, or 8.92%, to $65.23 after the deal was announced. MAJOR MOVERS: Among the notable gainers was Celldex Therapeutics (CLDX), which advanced $4.09, or 28.88%, to $18.25 after the company reported it saw a statistically significant overall survival benefit, along with an increase in clinically meaningful tumor shrinkage, in a sub-group of its study of a drug to treat a specific type of brain tumor. Also higher was Amicus Therapeutics (FOLD), which rose $1.01, or 17.75%, to $6.70 after the company announced additional data on secondary endpoints from its second Phase 3 study of its treatment for Fabry disease. Among the noteworthy losers was William Lyon Homes (WLH), which fell $3.52, or 15.53%, to $19.14 after the company announced that it intends to offer, subject to market and other conditions, 1M tangible equity units, which will consist of a prepaid stock purchase contract and an amortizing note. Also lower were shares of DreamWorks (DWA), which dropped $3.71, or 14.26%, to $22.31 after multiple media outlets reported that talks about a takeover of the company by Hasbro (HAS) had ended. INDEXES: The Dow gained 13.01, or 0.07%, to 17,647.75, the Nasdaq lost 17.54, or 0.37%, to 4,671.00, and the S&P 500 added 1.50, or 0.07%, to 2,041.32.
12:48 EDTCLDXCelldex volatility decreases after positive interim update
Celldex November call option implied volatility is at 69, December is at 65, January is at 64; compared to its 26-week average of 73 according to Track Data, suggesting decreasing price movement after the company on Friday afternoon reported interim positive data for its brain tumor treatment, rindopepimut.
12:27 EDTCLDXOn The Fly: Midday Wrap
Subscribe for More Information
11:37 EDTCLDXCelldex soars after reporting results from brain tumor treatment study
Subscribe for More Information
11:11 EDTCLDXHigh option volume stocks:
Subscribe for More Information
09:34 EDTCLDXiPath S&P 500 VIX Short-Term Futures are recently up 19c to 28.86
Subscribe for More Information
08:19 EDTCLDXCelldex Rindo data looks like 'home run,' says Cowen
Subscribe for More Information
07:12 EDTCLDXCelldex data better than expected, says Cantor
Cantor believes that data from the Phase II trial of Celldex's rindopepimut in EGFRvIII-positive glioblastoma multiforme patients exceed expectations. The firm thinks the data is likely to trigger a turning point in the shares. Cantor keeps a $33 price target and Buy rating on the stock.
November 14, 2014
17:27 EDTMNKPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
15:57 EDTCLDXCelldex to meet with FDA, propose accelerated approval filing, Feuerstein says
Subscribe for More Information
15:42 EDTCLDXCelldex sees significant survival benefit in Avastin-naive phase 2 trial
Subscribe for More Information
09:51 EDTMNKMallinckrodt management to meet with Oppenheimer
Meeting to be held in Europe on November 20 hosted by Oppenheimer.
November 13, 2014
10:44 EDTMNKMallinckrodt news on generic Concerta positive for Actavis, says BMO Capital
Subscribe for More Information
08:36 EDTCLDXCelldex to host conference call
Subscribe for More Information
08:20 EDTMNKMallinckrodt could be down $6-$8 on FDA reclassification, says UBS
Subscribe for More Information
07:24 EDTASGNSunTrust to hold a conference
Subscribe for More Information
07:10 EDTCLDXSociety for NeuroOncology to hold a meeting
Subscribe for More Information
06:17 EDTFOXASony unveils PlayStation Vue, a cloud-based TV service
Subscribe for More Information
06:11 EDTMNKMallinckrodt responds to FDA expected reclassification of methylphenidate ER
Mallinckrodt has been informed by the FDA that the agency has reason to believe that the company’s methylphenidate hydrochloride extended-release, or ER, tablets, USP may not be therapeutically equivalent to the category reference drug Concerta. As a result, the agency indicated that it has reclassified Mallinckrodt’s ANDA 202608 for methylphenidate ER dosage strengths of 27mg, 36 mg and 54 mg from AB to BX. The agency said that this change was based on the application of its new Draft Guidance for determining bioequivalence of methylphenidate hydrochloride products just published on November 6, 2014. Although the Draft Guidance has an open comment period through January 5, 2015, the agency nevertheless confirmed that this change would be reflected on November 13, 2014 in the on-line Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Mallinckrodt strongly believes its methylphenidate ER products are safe and effective when used in accordance with the approved labels. Mark Trudeau, president and CEO of Mallinckrodt stated, “We believe that the FDA’s actions are not supported by sound scientific evidence and not consistent with the best interests of patients." Mallinckrodt methylphenidate ER products have consistently met all quality specifications and the regulatory requirements originally defined by the FDA, and in the 21 months since launch more than 88M doses of these products have been prescribed. In that time, and across all of those patient exposures, the company has received only 68 confirmed adverse events related to a lack of efficacy when the patient switched from the reference listed drug to the company’s methylphenidate ER products.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use